HK1156326A1 - Anti-hepcidin-25 selective antibodies and uses thereof - Google Patents

Anti-hepcidin-25 selective antibodies and uses thereof

Info

Publication number
HK1156326A1
HK1156326A1 HK11110483.0A HK11110483A HK1156326A1 HK 1156326 A1 HK1156326 A1 HK 1156326A1 HK 11110483 A HK11110483 A HK 11110483A HK 1156326 A1 HK1156326 A1 HK 1156326A1
Authority
HK
Hong Kong
Prior art keywords
hepcidin
selective antibodies
antibodies
selective
Prior art date
Application number
HK11110483.0A
Other languages
English (en)
Inventor
Donmienne Doen Mun Leung
Peng Luan
Ying Tang
Derrick Ryan Witcher
Pia Pauliina Yachi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1156326A1 publication Critical patent/HK1156326A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK11110483.0A 2008-08-06 2011-10-04 Anti-hepcidin-25 selective antibodies and uses thereof HK1156326A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8655708P 2008-08-06 2008-08-06
PCT/US2009/052044 WO2010017070A1 (en) 2008-08-06 2009-07-29 Anti-hepcidin-25 selective antibodies and uses thereof

Publications (1)

Publication Number Publication Date
HK1156326A1 true HK1156326A1 (en) 2012-06-08

Family

ID=41165490

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11110483.0A HK1156326A1 (en) 2008-08-06 2011-10-04 Anti-hepcidin-25 selective antibodies and uses thereof

Country Status (20)

Country Link
US (1) US8609817B2 (xx)
EP (1) EP2328931B1 (xx)
JP (1) JP5730200B2 (xx)
KR (1) KR101462307B1 (xx)
CN (1) CN102112489B (xx)
AU (1) AU2009279865B2 (xx)
BR (1) BRPI0916624A2 (xx)
CA (1) CA2733497C (xx)
DK (1) DK2328931T3 (xx)
EA (1) EA201170312A1 (xx)
ES (1) ES2432018T3 (xx)
HK (1) HK1156326A1 (xx)
IL (1) IL210643A (xx)
MX (1) MX2011001363A (xx)
NZ (1) NZ590863A (xx)
PL (1) PL2328931T3 (xx)
PT (1) PT2328931E (xx)
UA (1) UA103032C2 (xx)
WO (1) WO2010017070A1 (xx)
ZA (1) ZA201100261B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4571620B2 (ja) * 2003-04-01 2010-10-27 インセルム（アンスティチュ・ナショナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 肝炎ｃウイルスｅ１ｅ２複合体に対する抗体、ｈｃｖ粒子の組成物及び医薬組成物
PE20091261A1 (es) * 2007-11-02 2009-08-17 Lilly Co Eli Anticuerpos anti-hepcidina
CA2808392C (en) 2010-08-16 2020-03-10 Pieris Ag Binding proteins for hepcidin
DK2791684T3 (da) 2011-12-12 2017-11-27 Pieris Pharmaceuticals Gmbh Fremgangsmåder til forebyggelse eller behandling af forstyrrelser ved forøgelse af biotilgængeligheden af jern og relateret farmaceutisk formulering
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
US20140120560A1 (en) * 2012-10-26 2014-05-01 Claresa Levetan Generation of new pancreatic beta cells
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
WO2014152006A2 (en) 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
DK3052522T3 (da) * 2013-10-03 2020-02-24 Biocare Medical Llc Anti-sox 10 antistofsystemer og -fremgangsmåder
JPWO2016027469A1 (ja) * 2014-08-21 2017-06-01 国立大学法人旭川医科大学 ヘプシジンのスプライシングバリアント並びに該バリアントを指標とした癌の診断方法
CA2961917A1 (en) * 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
EP3268027B1 (en) 2015-03-13 2022-11-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Hepcidin antagonists for use in the treatment of inflammation
CA3038894A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
EA201991204A1 (ru) 2016-12-22 2019-12-30 Университа Дельи Студи Манья Греча Катандзаро Моноклональное антитело против уникального сиалогликозилированного опухолеассоциированного эпитопа cd43
WO2018234538A1 (en) 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTAGONIST OR AGONIST OF HEPCIDINE FOR USE IN THE TREATMENT OF DYSREGULATION OF MO AND / OR MN METABOLISM
CN109948371B (zh) * 2019-03-07 2021-06-25 深圳市智税链科技有限公司 为区块链节点发放身份证书的方法及相关装置

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383254A1 (en) 1999-06-02 2000-12-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6262247B1 (en) 1999-08-30 2001-07-17 Incyte Genomics, Inc. Polycyclic aromatic hydrocarbon induced molecules
ES2326469T5 (es) * 2001-05-25 2018-05-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uso de hepcidina para preparar un medicamento para tratar trastornos de la homeostasis del hierro
CN1173737C (zh) 2002-10-21 2004-11-03 钱忠明 Hepcidin(海魄喜定)在制药中的应用
RU2359268C2 (ru) 2002-11-19 2009-06-20 ДиАрДжи ИНТЕРНЭШНЛ, ИНК. Способ диагностики заболеваний путем скрининга тканей, крови или жидкостей организма животных или человека на предмет обнаружения нефизиологических уровней гепсидина и его терапевтическое применение
US8017737B2 (en) * 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US20050033029A1 (en) 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
EP1673465A4 (en) 2003-09-29 2008-04-30 Biosite Inc PROCESS AND COMPOSITIONS FOR SEPSIS DIAGNOSIS
WO2005035753A1 (ja) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
AU2006223374B2 (en) * 2005-03-11 2011-07-21 Aspira Women’s Health Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
AU2008214386B2 (en) 2007-02-02 2013-09-19 Amgen Inc Hepcidin and hepcidin antibodies
GR1006896B (el) * 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
JP2010539969A (ja) * 2007-10-02 2010-12-24 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） ヒトヘプシジンに対して特異性を有する抗原結合タンパク質
PE20091261A1 (es) * 2007-11-02 2009-08-17 Lilly Co Eli Anticuerpos anti-hepcidina
EP2620448A1 (en) 2008-05-01 2013-07-31 Amgen Inc. Anti-hepcidin antibodies and methods of use

Also Published As

Publication number Publication date
US8609817B2 (en) 2013-12-17
CN102112489B (zh) 2014-05-14
IL210643A (en) 2015-09-24
WO2010017070A1 (en) 2010-02-11
PL2328931T3 (pl) 2014-01-31
ES2432018T3 (es) 2013-11-29
UA103032C2 (uk) 2013-09-10
AU2009279865A1 (en) 2010-02-11
EP2328931A1 (en) 2011-06-08
BRPI0916624A2 (pt) 2015-12-01
KR101462307B1 (ko) 2014-11-17
AU2009279865B2 (en) 2013-10-10
CN102112489A (zh) 2011-06-29
KR20110031963A (ko) 2011-03-29
IL210643A0 (en) 2011-03-31
NZ590863A (en) 2012-10-26
MX2011001363A (es) 2011-04-26
EP2328931B1 (en) 2013-08-14
US20110189190A1 (en) 2011-08-04
DK2328931T3 (da) 2013-09-30
CA2733497A1 (en) 2010-02-11
JP2011530514A (ja) 2011-12-22
CA2733497C (en) 2015-06-02
ZA201100261B (en) 2012-06-27
JP5730200B2 (ja) 2015-06-03
EA201170312A1 (ru) 2012-03-30
PT2328931E (pt) 2013-11-07

Similar Documents

Publication Publication Date Title
IL250624A0 (en) Anti-fgfr3 antibodies and methods of using them
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
IL216731A (en) And antibodies against p95 – her2 and their uses
HK1156326A1 (en) Anti-hepcidin-25 selective antibodies and uses thereof
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
HK1142341A1 (en) Anti-hepcidin antibodies and uses thereof
PL2099826T3 (pl) Przeciwciało przeciwko beta-amyloidowi i jego zastosowania
ZA201107486B (en) Anti-tnf-x antibodies and their uses
EP2494062A4 (en) ANTI-GLP-1R ANTIBODIES AND THEIR USES
PL2354161T3 (pl) Przeciwciało anty -NR10 i jego zastosowanie
EP2334330A4 (en) ANTI-CD147 ANTIBODIES, METHODS, AND USES
IL207129A0 (en) Ron antibodies and uses thereof
HK1195776A1 (zh) -α 抗-α 抗體及其應用
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
HK1210026A1 (en) Thiol-functionalising reagents and their uses
SI2354161T1 (sl) Anti-NR10 protitelo in njegova uporaba
EP2388320A4 (en) ANTI-HS6ST2 ANTIBODIES AND USE THEREOF
IL219136A0 (en) Anti-hepsin antibodies and methods using same
GB0903151D0 (en) Antibody uses and methods
IL214527A0 (en) Anti-mst1r antibodies and uses thereof
HK1158977A1 (zh) 抗膜鐵轉運蛋白 單克隆抗體及其用途
GB0812277D0 (en) Antibody and uses thereof
ZA200905136B (en) Anti-robo4 antibodies and uses therefor

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170729